Table II. Impact of HER2-immunohistochemical expression on relapse-free survival (RFS) in hormonal receptor-positive and HER2-negative early breast cancer patients.

HER2: Human epidermal growth factor receptor-2; ISH: in situ hybridization; NR: not reached; IDC: infiltrative ductal carcinoma; ILC: infiltrative lobular carcinoma.